Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FERM and PDZ domain-containing protein 1 (FRMPD1) is a large, multi-domain scaffold/adaptor protein containing a FERM domain and a PDZ domain.[2][4] It functions as a versatile adaptor protein that modulates key signaling pathways and cellular processes, notably by participating in the regulation of cell polarity, spindle orientation (via interaction with LGN and AGS3), and Hippo pathway activation through binding to WWC3.[2][4] In cancer biology, especially in non-small cell lung cancer, FRMPD1 acts as a tumor suppressor by activating the Hippo pathway, inhibiting YAP nuclear translocation, thereby reducing cell proliferation and invasion; its reduced expression correlates with poor prognosis.[4] FRMPD1 is expressed in a tissue-specific manner, including documented retinal-specific expression, but is not known to be a direct therapeutic target or receptor for any approved drugs.[2][4][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FERM and PDZ domain-containing protein 1 (FRMPD1).